Replies to post #399189 on NorthWest Biotherapeutics Inc (NWBO)

[anders2211]

and there is that.

So Duffy did not receive options and Innes did...

[biosectinvestor]

And of course, not receive any award, no incentive to stay until it vested. But the lack of an award communicates that they apparently did not expect him to stay long, and thus did not incentivize it.

[JerryCampbell]

You're wrong about Duffy and Innes being nwbo corporate officers. There is a list of "Executive Officers" in the proxy statement, and they're not on it.

https://www.sec.gov/Archives/edgar/data/1072379/000110465920039528/tm2013863-1_def14a.htm
https://www.sec.gov/Archives/edgar/data/1072379/000110465921051466/tm212568-1_def14a.htm

Jean Davis was hired as CFO, clearly an officer role. She was on the list of officers for 2020, but not 2021 when no longer in that role.

Duffy and Innes were hired as VPs, but not C-suite roles.

I'm curious where you saw Innes' compensation detailed. He's not mentioned in any proxy statements. Don't recall anything in 10-K or 10-Q. There is nothing in the PR about hiring him. He has never filed a Form 4 (and in my view is not required to file).

[exwannabe]

I actually believe as a VP Duffy would be considered an officer of the company.

So then you believe NWBO violated SEC law by not disclosing his compensation or his departure.

Glad you, biosec and Anders consider violations of securities law to be a reason to invest. Many would not.

BTW: he clearly was not a named officer. Those positions are defined by the charter and BOD, not the SEC. He was not on that short list.